About Natera

About Natera

Natera is a rapidly-growing diagnostics company with proprietary bioinformatics and molecular technology for analyzing DNA. Natera’s complex technology has been proven clinically and commercially in the prenatal testing space and the Company is actively researching its applications in the liquid biopsy space for developing products with oncology applications.

Since 2009, Natera has launched seven molecular diagnostic tests, many of which are available through major health plans accounting for more than 140 million covered lives in the United States. The Company’s own robust laboratory processes thousands of genetic tests per month.

Natera’s goal is to transform the way people – both providers and patients – respond to and manage genetic diseases.

Learn More About Natera

Stock Information

NTRA (Common Stock)
ExchangeNASDAQ CM (US Dollar)
Price$13.25
Change (%) Stock is Up 0.41 (3.19%)
Volume238,417
Data as of 07/27/16 4:00 p.m. ET
Minimum 15 minute delay
Refresh quote
Stock chart for: NTRA.O.  Currently trading at $13.25 with a 52 week high of $18.88 and a 52 week low of $6.52.

Recent News

Unilabs Selects Natera, Inc.'s Panorama® Non-Invasive Prenatal Test (NIPT), Further Expanding Natera's Global Constellation™ Technology Transfer Business - 07/18/16
SAN CARLOS, Calif., July 18, 2016 /PRNewswire/ -- Natera (NASDAQ: NTRA),a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, and Swiss-based Unilabs, one of Europe's leading providers of clinical laboratory testing ... More»
Natera Announces that the U.S. Supreme Court Denies Petition to Review '540 Patent Invalidation - 06/30/16
SAN CARLOS, Calif., June 30, 2016 /PRNewswire/ -- Natera (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, announced that the U.S. Supreme Court declined to review the Federal Circuit's determinat... More»
Natera and Illumina Extend Supply Agreement, Broaden Existing Partnership to Include Oncology Field - 06/29/16
SAN CARLOS, Calif., June 29, 2016 /PRNewswire/ -- Natera (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced the extension of its supply agreement with Illumina, Inc., for up to 10 y... More»
Natera Reports First Quarter 2016 Financial Results - 05/10/16
SAN CARLOS, Calif., May 10, 2016 /PRNewswire/ -- Natera,  Inc. (NASDAQ:  NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today reported financial results for the first quarter ended March 31, 2016 and pr... More»
Natera Announces First Quarter Earnings Conference Call - 05/03/16
SAN CARLOS, Calif., May 3, 2016 /PRNewswire/ -- Natera, Inc. (NASDAQ:  NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that it will release results for its first quarter ended March 31, 2... More»

Upcoming Events

There are currently no events scheduled.

Recent Presentations

There are currently no items available.

The information provided in this area of the website is maintained by a third-party service. Natera is not responsible for the accuracy, currency or completeness of the information contained herein.
Data provided by Nasdaq. Minimum 15 minutes delayed.
Shareholder Tools